voclosporin ophthalmic solution

DRUG2 trials

Sponsors

Lux Biosciences, Inc., Aurinia Pharmaceuticals Inc.

Conditions

Dry EyeKeratoconjunctivitis Sicca

Phase 1

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

CompletedNCT00851734

Lux Biosciences, Inc.Keratoconjunctivitis Sicca

Start: 2009-02-28End: 2009-04-30Updated: 2012-06-22

Phase 2

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

CompletedNCT03597139

Aurinia Pharmaceuticals Inc.Dry Eye

Start: 2018-08-13End: 2018-12-13Updated: 2021-07-08